Literature DB >> 11889071

Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis.

T ten Hove1, B van den Blink, I Pronk, P Drillenburg, M P Peppelenbosch, S J H van Deventer.   

Abstract

BACKGROUND: Crohn's disease is characterised by a chronic relapsing inflammation of the bowel in which proinflammatory cytokines play an important perpetuating role. Mitogen activated protein kinase p38 (p38 MAPK) has been established as a major regulator of the inflammatory response, especially with regard to production of proinflammatory cytokines, but its role in inflammatory bowel disease is unexplored. In this paper we describe the effects of a specific p38 MAPK inhibitor, SB 203580, in trinitrobenzene sulphonic acid (TNBS) induced colitis in mice.
RESULTS: SB 203580 had a dichotomal effect in TNBS mice. Weight loss of TNBS mice treated with SB 203580 was significantly worse and colon weight on sacrifice was significantly increased in MAPK inhibitor treated TNBS mice (229.2 mg and 289.1 mg, respectively). However, the total number of cells in the caudal lymph node decreased to 188.8 x 10(4) cells in SB 203580 treated TNBS mice compared with 334 x 10(4) cells in vehicle treated mice. CD3/CD28 double stimulated caudal lymph node cells of SB 203580 treated mice showed decreased interferon gamma production but increased tumour necrosis factor alpha production. The concentration of interleukin 12p70 in colon homogenates was significantly decreased in SB 203580 treated mice whereas concentrations of interleukin 12p40, tumour necrosis factor alpha, and interleukin 10 were similar in vehicle and SB 203580 treated TNBS mice.
CONCLUSION: Our results reveal a dichotomy in p38 MAPK action during experimental colitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889071      PMCID: PMC1773163          DOI: 10.1136/gut.50.4.507

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  42 in total

1.  Activation of p38 mitogen-activated protein kinase in vivo selectively induces apoptosis of CD8(+) but not CD4(+) T cells.

Authors:  C Merritt; H Enslen; N Diehl; D Conze; R J Davis; M Rincón
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

2.  Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice.

Authors:  I J Fuss; T Marth; M F Neurath; G R Pearlstein; A Jain; W Strober
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

3.  Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.

Authors:  A M Badger; J N Bradbeer; B Votta; J C Lee; J L Adams; D E Griswold
Journal:  J Pharmacol Exp Ther       Date:  1996-12       Impact factor: 4.030

4.  Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-alpha and release of arachidonic acid in mast cells. Indications of communication between p38 and p42 MAP kinases.

Authors:  C Zhang; R A Baumgartner; K Yamada; M A Beaven
Journal:  J Biol Chem       Date:  1997-05-16       Impact factor: 5.157

Review 5.  Current concepts of the pathogenesis of inflammatory bowel disease.

Authors:  F Shanahan
Journal:  Ir J Med Sci       Date:  1994-12       Impact factor: 1.568

Review 6.  Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.

Authors:  R B Sartor
Journal:  Gastroenterol Clin North Am       Date:  1995-09       Impact factor: 3.806

7.  Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site.

Authors:  P R Young; M M McLaughlin; S Kumar; S Kassis; M L Doyle; D McNulty; T F Gallagher; S Fisher; P C McDonnell; S A Carr; M J Huddleston; G Seibel; T G Porter; G P Livi; J L Adams; J C Lee
Journal:  J Biol Chem       Date:  1997-05-02       Impact factor: 5.157

8.  SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1.

Authors:  A Cuenda; J Rouse; Y N Doza; R Meier; P Cohen; T F Gallagher; P R Young; J C Lee
Journal:  FEBS Lett       Date:  1995-05-08       Impact factor: 4.124

9.  Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine.

Authors:  J Raingeaud; S Gupta; J S Rogers; M Dickens; J Han; R J Ulevitch; R J Davis
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

10.  The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor.

Authors:  R Beyaert; A Cuenda; W Vanden Berghe; S Plaisance; J C Lee; G Haegeman; P Cohen; W Fiers
Journal:  EMBO J       Date:  1996-04-15       Impact factor: 11.598

View more
  38 in total

1.  Uncoupling the p38 MAPK kinase in IBD: a double edged sword?

Authors:  V Arulampalam; S Pettersson
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

Review 2.  Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets.

Authors:  D W Hommes; M P Peppelenbosch; S J H van Deventer
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

3.  Amelioration of dextran sulfate sodium-induced colitis by neuropeptide Y antisense oligodeoxynucleotide.

Authors:  Xue Hua Pang; Tian Ke Li; Qin Xie; Fu Qian He; De Jun Cui; You Qin Chen; Xiao Li Huang; Hua Tian Gan
Journal:  Int J Colorectal Dis       Date:  2010-06-05       Impact factor: 2.571

4.  The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis.

Authors:  Kiran Assi; Rex Pillai; Antonio Gómez-Muñoz; David Owen; Baljinder Salh
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

5.  Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease.

Authors:  G Docena; L Rovedatti; L Kruidenier; A Fanning; N A B Leakey; C H Knowles; K Lee; F Shanahan; K Nally; P G McLean; A Di Sabatino; T T MacDonald
Journal:  Clin Exp Immunol       Date:  2010-08-20       Impact factor: 4.330

6.  Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease.

Authors:  P Rosenstiel; J Agnholt; J Kelsen; V Medici; G H Waetzig; D Seegert; S Schreiber
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

7.  An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice.

Authors:  Kanna Kobayashi; Shuo-Wang Qiao; Masaru Yoshida; Kristi Baker; Wayne I Lencer; Richard S Blumberg
Journal:  Gastroenterology       Date:  2009-08-04       Impact factor: 22.682

8.  Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease.

Authors:  Motoyuki Otsuka; Young Jun Kang; Jianlin Ren; Huiping Jiang; Yinbin Wang; Masao Omata; Jiahuai Han
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

9.  IL-2 regulates SEB induced toxic shock syndrome in BALB/c mice.

Authors:  Aslam Ali Khan; Shilpee Priya; Bhaskar Saha
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

10.  Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells.

Authors:  Satya Prakash; Aleksandra Malgorzata Urbanska
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.